SCHEMBL7799158

SCHEMBL7799158

CCCCCCCCCCOC1COC(c2ccccc2)OC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.40
ALDH1A1 P00352 2/20 0.39
TSHR P16473 2/20 0.39
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
HCRTR2 O43614 1/20 0.38
MEN1 O00255 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
LTA4H P09960 1/20 0.37
GBA1 P04062 1/20 0.37
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPK1 P28482 1/20 0.36
PTAFR P25105 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215031 1.00 PPARG (0.40) PPARGALDH1A1TSHRLMNATDP1
SCHEMBL2216976 1.00 PPARG (0.40) PPARGALDH1A1TSHRLMNATDP1
SCHEMBL11663818 1.00 PPARG (0.40) PPARGALDH1A1TSHRLMNATDP1
SCHEMBL2219048 1.00 PPARG (0.40) PPARGALDH1A1TSHRLMNATDP1
SCHEMBL18612429 0.94 MEN1 (0.40) PPARGTSHRTDP1HCRTR2MEN1
SCHEMBL12369625 0.92 MEN1 (0.43) TSHRTDP1HCRTR2MEN1CYP2C19
SCHEMBL2219973 0.92 SOAT2 (0.37) PPARGHCRTR2FAAH
SCHEMBL7108821 0.88 ALDH1A1 (0.37) ALDH1A1
SCHEMBL2361796 0.88 MEN1 (0.42) ALDH1A1TSHRHCRTR2MEN1CYP2C19
SCHEMBL8974955 0.84 TP53 (0.51) TSHRMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021198725-A1 FOSALVUDINE AND FOZIVUDINE TIDOXIL FOR USE IN THE TREATMENT OF COVID-19, AND USE OF THE STRUCTURALLY SIMPLIFIED DERIVATIVES THEREOF CHIRACON GMBH (DE) 2021-10-07 WO claimed
WO-2021198725-A1 FOSALVUDINE AND FOZIVUDINE TIDOXIL FOR USE IN THE TREATMENT OF COVID-19, AND USE OF THE STRUCTURALLY SIMPLIFIED DERIVATIVES THEREOF CHIRACON GMBH (DE) 2021-10-07 WO disclosed
US-10758483-B2 Fluoropolymer emulsions with perhalogenated stabilizer for the delivery of hydrophobic drugs WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2020-09-01 US disclosed
US-10426727-B2 Fluoropolymer emulsions with branched semifluorinated block copolymer or phospholipid surfactant for the delivery of hydrophobic drugs WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2019-10-01 US disclosed
US-20170100336-A1 Fluoropolymer Emulsions with Perhalogenated Stabilizer for the Delivery of Hydrophobic Drugs WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2017-04-13 US disclosed
US-20170049699-A1 Fluoropolymer Emulsions with Branched Semifluorinated Block Copolymer or Phospholipid Surfactant for the Delivery of Hydrophobic Drugs WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2017-02-23 US disclosed
WO-2015164781-A1 FLUOROPOLYMER EMULSIONS WITH BRANCHED SEMIFLUORINATED BLOCK COPOLYMER OR PHOSPHOLIPID SURFACTANT FOR THE DELIVERY OF HYDROPHOBIC DRUGS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-10-29 WO disclosed
WO-2015164756-A1 FLUOROPOLYMER EMULSIONS WITH PERHALOGENATED STABILIZER FOR THE DELIVERY OF HYDROPHOBIC DRUGS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-10-29 WO disclosed
EP-0854708-B1 LIPID ALCOHOLS AS NEW IMMUNOSUPPRESSIVE AND ANTIVIRAL DRUGS HEIDELBERG PHARMA HOLDING GMBH (DE) 2001-12-12 EP disclosed
US-6177469-B1 ANTIUTOR AGENTS; AUTOIMMUNE DISEASES HEIDELBERG PHARMA HOLDING GMBH (DE) 2001-01-23 US disclosed
EP-0854708-A1 LIPID ALCOHOLS AS NEW IMMUNOSUPPRESSIVE AND ANTIVIRAL DRUGS Roche Diagnostics GmbH (DE) 1998-07-29 EP disclosed
WO-1997014410-A1 LIPID ALCOHOLS AS NEW IMMUNOSUPPRESSIVE AND ANTIVIRAL DRUGS BOEHRINGER MANNHEIM GMBH (DE) 1997-04-24 WO disclosed
WO-1991005558-A1 USE OF LECITHIN ANALOGS AS ANTIVIRAL DRUGS AS WELL AS NEW COMPOUNDS BOEHRINGER MANNHEIM GMBH (DE) 1991-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10426727-B2 Fluoropolymer emulsions with branched semifluorinated block copolymer or phospholipid surfactant for the delivery of hydrophobic drugs FFAR3, FFAR1, FAU PPARG 260/4885ALDH1A1 4080/4885TSHR 1016/4885
US-20170049699-A1 Fluoropolymer Emulsions with Branched Semifluorinated Block Copolymer or Phospholipid Surfactant for the Delivery of Hydrophobic Drugs FFAR3, FFAR1, FAU PPARG 260/4885ALDH1A1 4080/4885TSHR 1016/4885
US-10758483-B2 Fluoropolymer emulsions with perhalogenated stabilizer for the delivery of hydrophobic drugs PFN1, FFAR1, FAU PPARG 172/4885ALDH1A1 3013/4885TSHR 1632/4885
US-20170100336-A1 Fluoropolymer Emulsions with Perhalogenated Stabilizer for the Delivery of Hydrophobic Drugs PFN1, FFAR1, FAU PPARG 172/4885ALDH1A1 3013/4885TSHR 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.